Modality
Degrader
MOA
STINGag
Target
CGRP
Pathway
Autophagy
MS
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
~Dec 2021
→ ~Mar 2023
Phase 2
Jun 2023
→ Feb 2026
Phase 2Current
NCT03711849
2,895 pts·MS
2023-06→2026-02·Not yet recruiting
2,895 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-201mo agoPh2 Data· MS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Not yet…
Catalysts
Ph2 Data
2026-02-20 · 1mo ago
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03711849 | Phase 2 | MS | Not yet recr... | 2895 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP |